Research
Compare
Two to six companies, their latest annual figures side by side, from SEC filings.
IKTInhibikase Therapeutics, Inc.
| Figure | IKTInhibikase Therapeutics, Inc.FY2024 · Dec |
|---|---|
| Revenue | $0.00 |
| Revenue, yoy | −100.0% |
| Net income | $48.26M |
| Net income, yoy | −75.4% |
| Net margin | — |
| Free cash flow | $27.80M |
| FCF margin | — |
| EPS, diluted | $0.49 |
Add another company.
Annual · FY2020–FY2024 · USD
From SEC EDGARSame fiscal periods, as filed